MTX-COVAB, a human-derived antibody against SARS-CoV-2, has shown efficacy against both the original virus as well as the UK variant. Memo is now preparing MTX-COVAB for clinical evaluation. In addition, the company was able to identify a very promising antibody candidate against the South African variant.
Using its microfluidic, single-cell molecular cloning and screening technologies to enable antibody repertoire mining and antibody discovery, Memo Therapeutics can discover novel antibodies at high speed, efficiency and sensitivity derived from recovered patient samples. This approach has enabled the company to also identify a very promising antibody candidate against the South African variant (B.1.351).